A Study of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis

NCT05265923 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

500

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis

Interventions

DRUG: CM310
OTHER: Placebo

Sponsor

Keymed Biosciences Co.Ltd